4.69

3.30% 0.15

Y Mabs Therapeutics Inc (YMAB)

Overview News Price History Option Chain Financials Discussions Forecast

Y Mabs Therapeutics Inc stock is traded at $4.69, with a volume of 107.04K. It is up +3.30% in the last 24 hours and down -1.47% over the past month. Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.

Previous Close:

$4.54

Open:

$4.52

24h Volume:

107.04K

Relative Volume:

0.27

Market Cap:

$222.93M

Revenue:

$84.82M

Net Income/Loss:

$-21.43M

P/E Ratio:

-9.5714

EPS:

-0.49

Net Cash Flow:

$-27.23M

1W Performance:

+7.82%

1M Performance:

-1.47%

6M Performance:

-66.97%

1Y Performance:

-68.96%

1-Day Range:

$4.505

$4.73

1-Week Range:

$4.395

$5.44

52-Week Range:

$3.86

$17.78

Y Mabs Therapeutics Inc Stock (YMAB) Company Profile

Name

Y Mabs Therapeutics Inc

Sector

Healthcare (1151)

Industry

Biotechnology (660)

Phone

646-885-8505

Address

202 CARNEGIE CENTER, PRINCETON, NY

Employee

107

Twitter

Next Earnings Date

2025-03-04

Latest SEC Filings

YMAB's Discussions on Twitter

Compare YMAB with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
YMAB Y Mabs Therapeutics Inc	4.69	222.93M	84.82M	-21.43M	-27.23M	-0.49
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-18-24	Initiated	Oppenheimer	Outperform
Aug-16-24	Initiated	Cantor Fitzgerald	Overweight
Jun-28-24	Initiated	Truist	Buy
May-10-23	Upgrade	Wedbush	Neutral → Outperform
Apr-03-23	Downgrade	Guggenheim	Buy → Neutral
Jan-27-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Jan-05-23	Downgrade	Cowen	Outperform → Market Perform
Dec-02-22	Downgrade	BofA Securities	Buy → Neutral
Oct-31-22	Downgrade	JP Morgan	Neutral → Underweight
Oct-31-22	Downgrade	Wedbush	Outperform → Neutral
Jul-06-22	Resumed	Canaccord Genuity	Buy
Jun-24-22	Initiated	BMO Capital Markets	Outperform
Feb-03-22	Resumed	Guggenheim	Buy
Nov-19-21	Resumed	Morgan Stanley	Equal-Weight
Nov-16-21	Downgrade	JP Morgan	Overweight → Neutral
May-07-21	Upgrade	BofA Securities	Neutral → Buy
Apr-23-21	Resumed	Cowen	Outperform
Mar-22-21	Resumed	JP Morgan	Overweight
Jan-15-21	Downgrade	BofA Securities	Buy → Neutral
Nov-09-20	Reiterated	H.C. Wainwright	Buy
May-05-20	Initiated	Barclays	Overweight
May-01-20	Initiated	Janney	Buy
Apr-29-20	Initiated	Morgan Stanley	Equal-Weight
Dec-24-19	Initiated	JP Morgan	Overweight
Nov-20-19	Initiated	Guggenheim	Buy
Sep-04-19	Initiated	Wedbush	Outperform
Apr-01-19	Initiated	H.C. Wainwright	Buy
Oct-16-18	Initiated	BTIG Research	Buy
Oct-16-18	Initiated	BofA/Merrill	Buy

View All

Y Mabs Therapeutics Inc Stock (YMAB) Latest News

02:52 AM

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World

02:52 AM

02:17 AM

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Short Interest Update - Defense World

02:17 AM

Apr 14, 2025

ExodusPoint Capital Management LP Buys New Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - The AM Reporter

Apr 14, 2025

Apr 13, 2025

KLP Kapitalforvaltning AS Acquires New Shares in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World

Apr 13, 2025

Apr 12, 2025

Prudential Financial Inc. Lowers Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World

Apr 12, 2025

Apr 11, 2025

Y-mAbs Therapeutics: A Yawn From The Market Means Opportunity (YMAB) - Seeking Alpha

Apr 11, 2025

Apr 09, 2025

Investing in Oncology: 4 Companies Driving Cancer Treatment Innovation - openPR.com

Apr 09, 2025

Apr 07, 2025

YMAB LAWSUIT: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact the Firm’s Attorneys, Securities Fraud Class Action Filed - ACCESS Newswire

Apr 07, 2025

Pediatric Neuroblastoma Treatment Market Size in 7MM - openPR.com

Apr 07, 2025

Apr 02, 2025

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) latest 12% decline adds to one-year losses, institutional investors may consider drastic measures - simplywall.st

Apr 02, 2025

Refractory Metastatic Melanoma Clinical and Non-Clinical - openPR.com

Apr 02, 2025

Mar 29, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Stake Boosted by Charles Schwab Investment Management Inc. - Defense World

Mar 29, 2025

Mar 27, 2025

(YMAB) Long Term Investment Analysis - news.stocktradersdaily.com

Mar 27, 2025

Mar 26, 2025

Top Premarket Decliners - MarketScreener

Mar 26, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Rating of “Moderate Buy” by Brokerages - Defense World

Mar 26, 2025

Mar 23, 2025

HC Wainwright Has Lowered Expectations for Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price - Defense World

Mar 23, 2025

Mar 21, 2025

Y-mabs therapeutics CEO Michael Rossi sells $20,368 in stock By Investing.com - Investing.com South Africa

Mar 11, 2025

Y-mabs therapeutics CBO Gad Thomas sells $56,536 in stock By Investing.com - Investing.com Australia

Mar 11, 2025

Y-mabs therapeutics CEO Michael Rossi sells $20,368 in stock - Investing.com

Mar 11, 2025

Y-mAbs Therapeutics Executives Sell Shares - TradingView

Mar 11, 2025